Influence of antipsychotic profile on cost of treatment of schizophrenia: A decision analysis approach

References

• Rice D P, Miller L S. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. Handbook of mental health economics and health policy. Volume I, Schizophrenia, M Moscarelli, A Rupp, N Sartorius. Wiley, Chichester 1996
   Google Scholar
• National Health Service Executive. Burdens of disease discussion paper. National Health Service Executive, Leeds 1996
   Google Scholar
• Jablensky A. Schizophrenia: recent epidemiologic issues. Epidemicol Rev 1995; 17: 10–20
   PubMed Web of Science ®Google Scholar
• Regier D A, Narrow W E, Rae D S, et al. The de facto US Mental and Addictive Disorders Service System: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85–94
   PubMed Web of Science ®Google Scholar
• Davies L M, Drummond M F. The economic burden of schizophrenia. Psychiatric Bull 1990; 14: 522–25
   Google Scholar
• Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Therapeutics 1997; 19: 128–38
   PubMed Web of Science ®Google Scholar
• Greenberg P E, Stilgin L E, Finkelstein S N, Bemdst E R. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–18
   PubMed Web of Science ®Google Scholar
• Davies L M, Drummond M F. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165(suppl 25)18–21
   Google Scholar
• Meltzer H Y, Cola P, Way L, et al. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8
   PubMed Web of Science ®Google Scholar
• Guest J F, Hart W M, Cookson R F, Lindstrom E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Economics 1996; 10: 59–67
   Google Scholar
• Glazer W M, Johnstone B M. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 58suppl 10: 50–4
   Google Scholar
• Beasley C M, Tollefson G D, Tran P V, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharm 1990; 14: 111–23
   Google Scholar
• Brown G R, Radford J M. Sertindole hydrochloride: a novel antipsychotic medication with a favourable side effect profile. South Med J 1997; 90: 691–3
   PubMedGoogle Scholar
• Wagstaff A J, Bryson H M. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 4: 370–400
   Web of Science ®Google Scholar
• Hummer M, Fleischhacker W W. Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal symptoms. CNS Drugs 1996; 5suppl 1: 13–20
   Google Scholar
• Kane J, Honingfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Pyschiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40
   PubMed Web of Science ®Google Scholar
• Marder S R, Meibach R C. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35
   PubMed Web of Science ®Google Scholar
• Arvanitis L A, Miller B G. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46
   PubMed Web of Science ®Google Scholar
• Tollefson G D, Beasley C M, Tran P V, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Pscyhiatry 1997; 154: 457–65
   PubMed Web of Science ®Google Scholar
• Weiden P J, Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bull 1995; 21: 419–29
   PubMed Web of Science ®Google Scholar
• Casey D E. Extrapyramidal syndromes: epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996; 5(suppl 1)1–12
   Google Scholar
• Kavanagh S, Opit L, Knapp M, Beecham J. Schizophrenia: shifting the balance of care. Soc Psychiatr Epidemiol 1995; 30: 206–12
   PubMed Web of Science ®Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great Britain. British Notional Formulary. The Pharmaceutical Press, Oxford September, 1992; 24.
   Google Scholar
• British Medical Association and Royal Pharmacological Society of Great Britain. British National Formulary. The Pharmaceutical Press, Oxford March, 1997; 33.
   Google Scholar
• Cooper S J, Butler A, Tweed J, et al. Zotepine in the prevention of relapse. Biol Psychiatry 1997; 42(suppl 1)41S
   Google Scholar
• Addington D E, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Therap 1993; 15: 917–26
   PubMed Web of Science ®Google Scholar
• Kinon B J, Lieberman J A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996; 124: 2–34
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Matsubara S, Lee J C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pK1 values. J Pharmacol Exper Ther 1989; 275: 238–46
   Google Scholar
• Mann J J. How medication compliance affects outcome. Psychiatric Ann 1986; 16: 567–70
   Web of Science ®Google Scholar
• Pool V E, Elder S T. A selected review of the literature and an empirical analysis of drug treatment compliance by schizophrenic patients. Int Rev Appl Psychol 1986; 35: 547–76
   Google Scholar
• Tran P V, Hamilton S H, Kuntz A J, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other treatment disorders. J Clin Psychopharmacol 1997; 17: 407–18
   PubMed Web of Science ®Google Scholar
• National Association of Commissioning GPs Executive. Report to the Secretary of State for Health on national standards for GP commissioning. National Association of Commissioning GPs, Nottingham 1996
   Google Scholar
• National Health Service Executive. Priorities and planning guidance for the NHS: 1998/9. National Health Service Executive, Leeds 1997
   Google Scholar
• Department of Health (1997) The new NHS. modem, dependable. Department of Health, London
   Google Scholar
• Amaddeo F, Beecham J, Bonizzato P, et al. The use of a case register to evaluate the costs of psychiatric care. Acta Psychiatr Scand 1997; 95: 189–98
   PubMed Web of Science ®Google Scholar
• Drummond M F, Knapp M RJ, Burns T P, et al. Methodological issues in the outcomes assessment of a new atypical antipsychotic. Europ Neuropsychopharmocol 1996; 6(suppl 4)126
   Google Scholar